332 results about "Snake venom" patented technology

The present invention is one kind snake venom cytozyme hemostatic containing blood coagulating factor, activator RVV-X and synergist snake venom thrombase. Preferably, the snake venom cytozyme hemostatic contains also serum albumin, for example human serum albumin. In addition, the present invention also discloses the preparation process and hemostatic use of high purity RVV-X.

The invention discloses a method for refining a polyvalent ASV (anti-snake venom) lyophilized serum, pertaining to an immune serum containing antibody which aims at least two kinds of antigens. The serum takes the venom of Ancistrodon acutus, Agkistrodon halys, Pit-vipers, bamboo snakes, adders and the like as the immune antigen which is inoculated into the bodies of animals after degerming and dialysis, and then titer immune serum after purification is used for collecting the antibody which is then desalted and lyophilized; mice are used for evaluating the LD50 of the virulence of the venom and the titer of the ASV serum; the antibody inoculated into the bodies of the animals is one of the venom, toxoid or snake venom or the composition thereof, and glutaraldehyde or formaldehyde is used for toxin detoxication; before immunity, anti-tetanic toxoid condensed antibody for human beings is used for carrying out minim gradual immunization on the animals, or an Emuade adjuvant is used for immunization purpose. The polyvalent ASV lyophilized serum complies with the biological product standards upon the tests and inspections of purity and specific activity, safety, pyrogen, hypersusceptibility, dissolution and the like; moreover, the serum can cure sufferers who are bitten by vipers with the advantages of high purity, low foreign protein, easy preservation and quick dissolving capacity.

Aliquots of extracts from ethnopharmacological plants that have activity against the effects of sarafotoxins present in snake venom are isolated and identified as antagonists of endothelin using a fluorescence-based assay. A process is provided for the identification of an antagonist of an endothelin selected from the group consisting of endothelin-1, endothelin-2, endothelin-3 and mixtures thereof. The process comprises extraction of ethnopharmacological plants with a solvent followed by evaporation of the solvent to form an aliquot containing at least one component of the extract, optionally purifying and isolating one or more component by chromatography, and subjecting the aliquot or purified component to a competitive fluorescent binding assay using biotinylated endothelin-1, wherein the plants having activity against the effects of one or more sarafotoxins present in snake venom.

The invention relates to phospholipase(s), isoforms, derivatives, mutants and/or fragments thereof, for the preparation of a medicament for the treatment and/or prevention of ischemia. Preferred is the use of secretory phospholipase, particularly phospholipase A₂, and even more particularly phospholipase A₂ derived from the snake venom of Naja sputatrix

The present invention is chicken yoke antibody (IgY) resisting Bengalese cobra venom and its preparation process. The preparation process includes water dilution to extract coarse IgY from chicken yoke, salting out IgY with ammonium sulfate, dissolving the precipitate in PBS, ultrafiltering to desalt, concentrating, anion exchanging chromatographic separation for further purifying IgY, ultrafiltering to desalt, concentrating, and freeze drying. The IgY exhibits single tape of molecular weight 200 KD in non-reductant SDS-PAGE and two tapes of molecular weight 65 KD and 35 KD separately in reductant SDS-PAGE, and has at least 13 dyeing strips of molecular weight 100-0.7 KD on PVDF film for Western Blot detection. The chicken yoke antibody (IgY) resisting Bengalese cobra venom may be used in preparing medicine and health food for preventing and/or treating snake bite, and in preparing reagent for detecting relevant snake venom.

The invention discloses a purification method, an extract and a preparation of cobra venom neurotoxin. The extract of the cobra venom neurotoxin is prepared from cobra crude venom through extraction and purification. A filter membrane filtering method is firstly adopted for removing germs, particles and macromolecular sensitizers in solution, the time and the cost are saved for the subsequent processes, and the safety of products is enhanced; an ion exchange method is adopted for eluting and separating the neurotoxin, and the separation of neurotoxin protein is improved; and finally, acetone is adopted for directly precipitating the cobra venom neurotoxin, and impurities in final products are removed. Compared with the prior art, the extract and the preparation obtained in the invention have the advantages that the product yield, the content and the purity are improved, the adverse reaction of the medicine is effectively reduced, the curative effect is improved, and the quality of products is ensured.

The invention discloses a method for detecting and identifying the variety of snake venom by utilizing an adaptor technology, belonging to the field of biomedicine verification and relating to a method for detecting snake venom by utilizing the adaptor technology. Specific to the problems complex compositions of snake venom and poor specificity and sensitivity of the traditional snake bite detection method, the invention adopts a depletion SELEX (Systematic Evolution of Ligands by Exponential Enrichment) technology, and an adaptor with high-degree snake venom species specificity is obtained through screening and is converted into a report adaptor so as to establish a novel method for quickly detecting snake venom.

The present invention discloses an anti-tumour snake venom cytotoxin and a production technique thereof, belonging to the fields of biochemistry and biological medicines. The snake venom cytotoxin of the present invention is derived from the prior lyophilized cobra venom powder. In the production technique of the present invention, the lyophilized cobra venom powder is resolved in the known buffer solution, and then on a SP-Sepharose H.P cation exchange column (5.0cm multipled by 29cm), gradiently eluted stage by stage by phosphate buffer and NaC1 at 10ml per tube and the flowing speed of 18ml per minute, a KTA Explorer protein purification system is used to monitor and collect eluting peaks, XII and XIII peaks with cytotoxic effects are collected, and via Source 30RPC reversed phase chromatography, cytotoxin XII and cytotoxin XIII, the molecular weight of which is about 6000 daltons to 7000 daltons and the isoelectric point of which is larger than 10, are respectively obtained. Compared with the purification step of the prior art, the production technique for producing the pure anti-tumour snake venom cytotoxin product without PLA2 has good rapid repeatability and is suitable for expanded production.

Purified multivalent and lyophilized antivenin and a use method belong to antibody immunity serums that aim at more than two antigens. The invention aims at preparing the multivalent antivenin by a plurality of lyophilized antivenins and the use method. The invention is characterized in that: the antigen-binding fragment F(ab)2 has 60 to 80 percent of lyophilized antiserum, the unit is mg per person, 342.5 to 1035 of vipers, 1177 to 3182 of agkistrodon acutus, 456 to 666 of adders, 1419 to 2128 of king cobras, 220 to 331 of coral snakes, 880 to 1320 of gold banded kraits, 3188 to 4782 of cobras are combined; the optimized combination is as follows: 635 of vipers, 1959 of agkistrodon acutus, 561 of adders, 1774 of king cobras, 276 of coral snakes, 1100 of gold banded kraits and 3985 of cobras. Blood circulation snake venom antiserum and nerves snake venom antiserum are respectively filled and measured. The use method is as follows: the antivenin that is diluted by sodium chloride and an anti-allergic agent, such as chlorphenamine maleate, are injected into muscle or a vein. The antivenin is prepared by only seven antivenins, and can effectively and in time treat injuries caused by various poisonous snakes in our country when the antiserum is directly injected in condition of the undetermined variety of poisonous snakes, and the invention reaches the advanced world level of the antivenin.

The invention discloses a snake venom metal protease inhibitor BJ46a capable of resisting attack and transference of tumor and application thereof, and belongs to the field of medical organism. In the invention, according to the BJ46a gene sequence (AF294836) in GenBank, the BJ46a full gene is designed and synthesized. An expression vector cloned to baculovirus can generate the recombined BJ46a protein capable of inhibiting the activity of the substrate metal protease in Sf9 insect cells, and in vivo and in vitro experiments show that the BJ46a protein has the functions of resisting the attack and transference of melanoma cells B16. The inhibitor adopts the genetic transfection technique, and can establish B16/pcDNA3.1HisC-BJ46a cell strains with stable transfection, and the in vivo and in vitro experiments prove that the BJ46a can inhibit the attack and transference of B16 cells at the gene level. The inhibitor is applied to preventing and treating the attack and transference of tumor, and has great application prospect.

The present invention provides a wheat germ cell-free protein synthesis system for high level expression of recombination snake venom kininogenase. According to the system, snake venom kininogenase gene of agkistrodon halys pallas is cloned through reverse transcription, wheat germ cell-free expression plasmid pCS<2+>/VK is constructed, a wheat germ extract is prepared, an in vitro transcription and translation system is established, the snake venom kininogenase is expressed and the system is optimized. The N terminal of the exogenous protein expressed by the expression system has the His protein tag, and a Ni column elution method is adopted to carry out purification, such that the subsequent purification of the recombinant protein is substantially simplified, the purification efficiency is high, and the cost is low. The exogenous protein further has biological activity, and provides the foundation for the next clinical study.

The invention discloses an application of physically-modified Chinese cobra venom in preparation of medicaments for treating acute and chronic nephrosis. The physically-modified Chinese cobra venom is obtained by dissolving Chinese cobra venom with deionized water, heating for denaturation and then performing renaturation; the heating temperature is controlled to be 50-100 DEG C, and the heating time is controlled to be 1 min-300 min. The invention finds that the heated and denaturated Chinese cobra venom can effectively reduce urine protein in acute and chronic nephrosis, reduce serum creatinine, and urea nitrogen, improve the pathological damage degree of the kidney, and recover kidney functions.

The invention discloses a method for catalytic synthesis of a dicoumarin compound through lipases. The method comprises the step: 4-hydroxycoumarin is adopted as a substrate, and subjected to a Knoevenagel-Michael cascade reaction through lipase catalyzing to generate the dicoumarin compound with a compound in the formula II. The dicoumarin compound can be used for treating thrombus, resisting HIV, and treating asthma, skin cancer and snake venom, and can further be used for antimicrobial treatment of certain staphylococcus aureus and staphylococcus epidermidis and preparing of analytical reagents; and according to the method, reacting conditions are mild, aftertreatment is easy, the substrate is widespread, a catalyst can be recycled, and the method is an economical and environment-friendly new method for synthesizing the dicoumarin compound.

The invention discloses a method of extracting defibrase from snake poison and preparing defibrase injection preparation, and the process of extracting defibrase includes the steps: preparing monoclonal antibody; preparing crude defibrase; preparing antibody affinity chromatography column; preparing defibrase; and the process of preparing the defibrase injection preparation includes the steps: taking and adding purified defibrase to a proper amount of injection water for dissolving so as to obtain a solution, adding 5-20g NaCl stabilizer to every 1000ml solution, making split charging and obtaining the defibrase injection preparation.